Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2176 - 2200 of 15152 in total

Tagraxofusp

Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018...
Approved
Investigational
Matched Description: … fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Enoxaparin

Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients...
Approved
Matched Description: … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various ... Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Pancrelipase protease

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.[A32742, L2543]...
Approved
Matched Description: … cleave peptide bonds and are involved in food digestion. ... Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and …
Matched Categories: … Enzymes and Coenzymes …

Buserelin

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Approved
Investigational
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Diacerein

Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2),...
Approved
Investigational
Matched Iupac: … 4,5-bis(acetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid …
Matched Description: … Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Artemotil

Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
Approved
Matched Description: … Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting ... schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum_ malaria and …
Matched Categories: … Artemisinin and derivatives ... Antiparasitic Products, Insecticides and Repellents …

Toripalimab

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1) - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the...
Approved
Investigational
Matched Description: … production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors. ... through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and ... PD-L2) to its target receptor (PD-1) results in the inhibition of T-cell proliferation and cytokine …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mebrofenin

Approved
Experimental
Matched Iupac: … 2-({[(3-bromo-2,4,6-trimethylphenyl)carbamoyl]methyl}(carboxymethyl)amino)acetic acid …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Donislecel

Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and …
Matched Categories: … Cellular and Gene Therapy …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. ... Clinical manifestations of MF include anemia and thrombocytosis. ... MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Conivaptan

Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Approved
Investigational
Matched Description: … Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). …

Onasemnogene abeparvovec

Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … to debilitating and often fatal muscle weakness. ... for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and ... complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing ... [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. ... IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eflapegrastim

Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … risk of morbidity and mortality. ... Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia ... [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Alteplase

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase...
Approved
Investigational
Matched Description: … alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and ... thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and ... alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Valproate bismuth

Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.
Approved

Ammonia N-13

Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. Ammonia N 13 Injection, USP is used for imaging...
Approved

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Approved
Matched Description: … It is 140 residues long, and is produced using E. coli. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Guanethidine

An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]
Approved
Matched Description: … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes …
Matched Categories: … guanethidine and diuretics ... Antiglaucoma Preparations and Miotics ... Guanidine Derivatives and Diuretics …

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the...
Approved
Investigational
Matched Description: … L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and ... dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alpha-1-proteinase inhibitor

Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Approved
Matched Description: … inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Isopropamide

Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Approved
Vet approved
Matched Description: … and hypermotility. ... It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity …
Matched Categories: … Alimentary Tract and Metabolism ... isopropamide and psycholeptics …

Bimekizumab

Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor,...
Approved
Investigational
Matched Description: … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. ... compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and ... of moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 2176 - 2200 of 15152 in total